Base de dados : MEDLINE
Pesquisa : D10.251.355.255.550.250.100 [Categoria DeCS]
Referências encontradas : 6761 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 677 ir para página                         

  1 / 6761 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:29318581
[Au] Autor:Vietto V; Franco JV; Saenz V; Cytryn D; Chas J; Ciapponi A
[Ad] Endereço:Family and Community Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
[Ti] Título:Prostanoids for critical limb ischaemia.
[So] Source:Cochrane Database Syst Rev;1:CD006544, 2018 01 10.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Peripheral arterial occlusive disease (PAOD) is a common cause of morbidity and mortality due to cardiovascular disease in the general population. Although numerous treatments have been adopted for patients at different disease stages, no option other than amputation is available for patients presenting with critical limb ischaemia (CLI) unsuitable for rescue or reconstructive intervention. In this regard, prostanoids have been proposed as a therapeutic alternative, with the aim of increasing blood supply to the limb with occluded arteries through their vasodilatory, antithrombotic, and anti-inflammatory effects. This is an update of a review first published in 2010. OBJECTIVES: To determine the effectiveness and safety of prostanoids in patients with CLI unsuitable for rescue or reconstructive intervention. SEARCH METHODS: For this update, the Cochrane Vascular Information Specialist searched the Specialised Register (January 2017) and the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 1). In addition, we searched trials registries (January 2017) and contacted pharmaceutical manufacturers, in our efforts to identify unpublished data and ongoing trials. SELECTION CRITERIA: Randomised controlled trials describing the efficacy and safety of prostanoids compared with placebo or other pharmacological control treatments for patients presenting with CLI without chance of rescue or reconstructive intervention. DATA COLLECTION AND ANALYSIS: Two review authors independently selected trials, assessed trials for eligibility and methodological quality, and extracted data. We resolved disagreements by consensus or by consultation with a third review author. MAIN RESULTS: For this update, 15 additional studies fulfilled selection criteria. We included in this review 33 randomised controlled trials with 4477 participants; 21 compared different prostanoids versus placebo, seven compared prostanoids versus other agents, and five conducted head-to-head comparisons using two different prostanoids.We found low-quality evidence that suggests no clear difference in the incidence of cardiovascular mortality between patients receiving prostanoids and those given placebo (risk ratio (RR) 0.81, 95% confidence interval (CI) 0.41 to 1.58). We found high-quality evidence showing that prostanoids have no effect on the incidence of total amputations when compared with placebo (RR 0.97, 95% CI 0.86 to 1.09). Adverse events were more frequent with prostanoids than with placebo (RR 2.11, 95% CI 1.79 to 2.50; moderate-quality evidence). The most commonly reported adverse events were headache, nausea, vomiting, diarrhoea, flushing, and hypotension. We found moderate-quality evidence showing that prostanoids reduced rest-pain (RR 1.30, 95% CI 1.06 to 1.59) and promoted ulcer healing (RR 1.24, 95% CI 1.04 to 1.48) when compared with placebo, although these small beneficial effects were diluted when we performed a sensitivity analysis that excluded studies at high risk of bias. Additionally, we found evidence of low to very low quality suggesting the effects of prostanoids versus other active agents or versus other prostanoids because studies conducting these comparisons were few and we judged them to be at high risk of bias. None of the included studies assessed quality of life. AUTHORS' CONCLUSIONS: We found high-quality evidence showing that prostanoids have no effect on the incidence of total amputations when compared against placebo. Moderate-quality evidence showed small beneficial effects of prostanoids for rest-pain relief and ulcer healing when compared with placebo. Additionally, moderate-quality evidence showed a greater incidence of adverse effects with the use of prostanoids, and low-quality evidence suggests that prostanoids have no effect on cardiovascular mortality when compared with placebo. None of the included studies reported quality of life measurements. The balance between benefits and harms associated with use of prostanoids in patients with critical limb ischaemia with no chance of reconstructive intervention is uncertain; therefore careful assessment of therapeutic alternatives should be considered. Main reasons for downgrading the quality of evidence were high risk of attrition bias and imprecision of effect estimates.
[Mh] Termos MeSH primário: Isquemia/tratamento farmacológico
Perna (Membro)/irrigação sanguínea
Doenças Vasculares Periféricas/tratamento farmacológico
Prostaglandinas/uso terapêutico
[Mh] Termos MeSH secundário: Alprostadil/uso terapêutico
Amputação/estatística & dados numéricos
Epoprostenol/uso terapêutico
Seres Humanos
Iloprosta/uso terapêutico
Isquemia/mortalidade
Perna (Membro)/cirurgia
Úlcera da Perna/tratamento farmacológico
Nafronil/uso terapêutico
Ácidos Nicotínicos/uso terapêutico
Pentoxifilina/uso terapêutico
Prostaglandinas/efeitos adversos
Ensaios Clínicos Controlados Aleatórios como Assunto
Vasodilatadores/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Nicotinic Acids); 0 (Prostaglandins); 0 (Vasodilator Agents); 42H8PQ0NMJ (Nafronyl); A99MK953KZ (Inositol Niacinate); DCR9Z582X0 (Epoprostenol); F5TD010360 (Alprostadil); JED5K35YGL (Iloprost); SD6QCT3TSU (Pentoxifylline)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180111
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD006544.pub3


  2 / 6761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29185789
[Au] Autor:Mou Y; Zhang Y; Guo C; Zhao J; Zhang Z; Zhou X; Dong J; Liao L
[Ad] Endereço:1 Division of Cardiology, Department of Internal Medicine, Shandong Provincial Hospital Affiliated to Shandong University , Jinan, China .
[Ti] Título:Integrated Treatment of Prostaglandin E1 and Angiotensin-Converting Enzyme Inhibitor in Diabetic Kidney Disease Rats: Possible Role of Antiapoptosis in Renal Tubular Epithelial Cells.
[So] Source:DNA Cell Biol;37(2):133-141, 2018 Feb.
[Is] ISSN:1557-7430
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:To investigate the therapeutic mechanisms underlying prostaglandin E1 (PGE1) and angiotensin-converting enzyme inhibitor (ACEI) on reducing urinary protein in diabetic kidney disease (DKD). DKD rats were established and randomly divided into four groups: PGE1 (10 µg/kg/day) (P group), ACEI (10 mg/kg/day) (A group), combination of PGE1 with ACEI treatment (P + A group), and saline treatment group (DKD group). Untreated rats were used as normal control (N group). Urinary albumin, endothelin-1 (ET-1), angiotensin II (AngII), TUNEL assay, Masson's trichrome staining, and immunohistochemistry staining for CD68 were evaluated in all groups. Ten days after treatment, urinary albumin was significantly decreased in the P and P + A groups (p < 0.01 vs. the DKD group). At the end of 8 weeks, the albumin was still significantly reduced in the P + A group (p < 0.05 vs. the A group). ET-1 and AngII were also significantly decreased in three treatment groups (p < 0.01 vs. the DKD group), especially in the P + A group. Few cells underwent apoptosis in glomerular regions in DKD rats, while amounts of apoptotic cells were seen in tubules regions. Further, apoptosis and the areas of fibrosis in tubulointerstitial were both decreased most in the P + A group compared with the DKD group. Apoptosis of renal tubular epithelial cells may participate in the development and progression of DKD in rats. Combination of PGE1 with AGEI remarkably protects renal function compared with PGE1 or ACEI monotherapy. The potential therapeutic mechanisms of PGE1 and AGEI might be via multiple targets and, at least in part, through inhibiting the apoptosis of renal tubular epithelial cells.
[Mh] Termos MeSH primário: Alprostadil/farmacologia
Inibidores da Enzima Conversora de Angiotensina/farmacologia
Diabetes Mellitus Experimental/complicações
Nefropatias Diabéticas/tratamento farmacológico
Nefrite Intersticial/tratamento farmacológico
[Mh] Termos MeSH secundário: Angiotensina II/sangue
Animais
Apoptose/efeitos dos fármacos
Diabetes Mellitus Experimental/sangue
Nefropatias Diabéticas/sangue
Nefropatias Diabéticas/etiologia
Avaliação Pré-Clínica de Medicamentos
Endotelina-1/sangue
Células Epiteliais/efeitos dos fármacos
Túbulos Renais/efeitos dos fármacos
Túbulos Renais/patologia
Macrófagos/imunologia
Masculino
Nefrite Intersticial/sangue
Nefrite Intersticial/etiologia
Ratos Wistar
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Endothelin-1); 11128-99-7 (Angiotensin II); F5TD010360 (Alprostadil)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171130
[St] Status:MEDLINE
[do] DOI:10.1089/dna.2017.3690


  3 / 6761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:28746468
[Au] Autor:Radojkovic M; Stojanovic M; Stanojevic G; Radojkovic D; Gligorijevic J; Ilic I; Stojanovic N
[Ad] Endereço:Surgery Department, School of Medicine, University of Nis, Nis, Serbia.
[Ti] Título:Ischemic preconditioning vs adenosine vs prostaglandin E1 for protection against liver ischemia/reperfusion injury.
[So] Source:Braz J Med Biol Res;50(8):e6185, 2017 Jul 20.
[Is] ISSN:1414-431X
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:Ischemia/reperfusion injury is still a major cause of morbidity and mortality during liver surgery and transplantation. A variety of surgical and pharmacological therapeutic strategies have been investigated to minimize the effects of ischemia/reperfusion. The aim of our study was to analyze and compare preventive influences of ischemic preconditioning, adenosine and prostaglandin E1 in the experimental model of hepatic ischemia/reperfusion injury. Adult chinchilla rabbits were divided into four groups: 10 rabbits subjected to liver ischemic preconditioning (3-min period of inflow occlusion followed by a 5-min period of reperfusion) followed by 45 min of Pringle maneuver; 10 rabbits subjected to pre-treatment with intraportal injection of adenosine followed by 45 min of Pringle maneuver; 10 rabbits subjected to pre-treatment with intraportal injection of prostaglandin E1 followed by 45 min of Pringle maneuver; and control group of 10 rabbits subjected to 45 min of inflow liver ischemia without any preconditioning. On the second postoperative day, blood samples were obtained and biochemical parameters of liver function were measured and compared. Liver tissue samples were also obtained and histopathological changes were compared. Based on biochemical and histopathological parameters, it was demonstrated that ischemic preconditioning provided the best protection against hepatic ischemia/reperfusion injury. This was probably due to a wider range of mechanisms of action of this method oriented to reduce oxidative stress and inflammation, and restore liver microcirculation and hepatocyte energy compared to the examined pharmacological strategies.
[Mh] Termos MeSH primário: Adenosina/uso terapêutico
Alprostadil/uso terapêutico
Precondicionamento Isquêmico/métodos
Hepatopatias/prevenção & controle
Fígado/irrigação sanguínea
Traumatismo por Reperfusão/prevenção & controle
[Mh] Termos MeSH secundário: Animais
Chinchila
Modelos Animais de Doenças
Feminino
Fígado/efeitos dos fármacos
Fígado/patologia
Masculino
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
F5TD010360 (Alprostadil); K72T3FS567 (Adenosine)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171204
[Lr] Data última revisão:
171204
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE


  4 / 6761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:28724039
[Au] Autor:Abuowda Y; Almeida RS; Oliveira AA; Pego P; Santos C; Matos-Costa J
[Ad] Endereço:Clinic of autoimmune diseases, Department of Internal Medicine - III, Hospital Distrital de Santarém, Santarém, Portugal.
[Ti] Título:Treatment of digital ulcers in systemic sclerosis: Case series study of thirteen patients and discussion on outcome.
[So] Source:Rev Assoc Med Bras (1992);63(5):422-426, 2017 May.
[Is] ISSN:1806-9282
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:Introduction:: In systemic sclerosis (SSc), digital ulcers (DU) are debilitating and recurrent. They are markers of prognosis and are associated with disability and mortality. Treatment strategies have been developed to block the proposed mechanisms of this complication. Objective:: Clinical description of a population of SSc patients with DU, treatment, complications and outcome. Method:: Analysis of 48 SSc patients meeting 2013 ACR-EULAR criteria, followed between 1999-2015; 13 patients had DU. Treatment protocol applied included cycles of 21 days of alprostadil, which can be repeated in the absence of DU healing. After DU healing, bosentan was initiated. Results:: DU healing was achieved with intravenous prostanoid in 12 patients; seven patients required repeated treatment for DU healing. Twelve patients were later treated with bosentan; three of them experienced recurrence of DU, while one was anti-B2-GPI positive. Four patients had soft tissue loss and three other suffered digital amputation, these being late diagnosis. Conclusion:: Younger patients and early referrals had better outcomes. Endothelin receptor antagonist toxicity should be monitored, particularly in patients previously exposed to hepatotoxic drugs.
[Mh] Termos MeSH primário: Alprostadil/uso terapêutico
Antagonistas dos Receptores de Endotelina/uso terapêutico
Dedos
Escleroderma Sistêmico/complicações
Úlcera Cutânea/tratamento farmacológico
Úlcera Cutânea/etiologia
Sulfonamidas/uso terapêutico
Vasodilatadores/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Relação Dose-Resposta a Droga
Feminino
Dermatoses da Mão/tratamento farmacológico
Dermatoses da Mão/etiologia
Dermatoses da Mão/patologia
Seres Humanos
Masculino
Meia-Idade
Reprodutibilidade dos Testes
Úlcera Cutânea/patologia
Fatores de Tempo
Resultado do Tratamento
Cicatrização/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Endothelin Receptor Antagonists); 0 (Sulfonamides); 0 (Vasodilator Agents); F5TD010360 (Alprostadil); Q326023R30 (bosentan)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170929
[Lr] Data última revisão:
170929
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170721
[St] Status:MEDLINE


  5 / 6761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28644845
[Au] Autor:Yang Y; Kim HJ; Woo KJ; Cho D; Bang SI
[Ad] Endereço:Department of Plastic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
[Ti] Título:Lipo-PGE1 suppresses collagen production in human dermal fibroblasts via the ERK/Ets-1 signaling pathway.
[So] Source:PLoS One;12(6):e0179614, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Dysregulation of collagen production contributes to various pathological processes, including tissue fibrosis as well as impaired wound healing. Lipo-prostaglandin E1 (Lipo-PGE1), a lipid microsphere-incorporated prostaglandin E1, is used as a vasodilator for the treatment of peripheral vascular diseases. Lipo-PGE1 was recently shown to enhance human dermal fibroblast (HDF) migration and in vivo wound healing. No published study has characterized the role of Lipo-PGE1 in collagen regulation in HDFs. Here, we investigated the cellular signaling mechanism by which Lipo-PGE1 regulates collagen in HDFs. Collagen production was evaluated by the Sircol collagen assay, Western blot analysis of type I collagen and real time PCR. Unexpectedly, Lipo-PGE1 decreased mRNA expression of collagen 1A1, 1A2, and 3A1. Lipo-PGE1 markedly inhibited type I collagen and total soluble collagen production. In addition, Lipo-PGE1 inhibited transforming growth factor-ß-induced collagen expression via Smad2 phosphorylation. To further investigate whether extracellular signal-regulated kinase (ERK)/Ets-1 signaling, a crucial pathway in collagen regulation, is involved in Lipo-PGE1-inhibited collagen production, cells were pretreated with an ERK-specific inhibitor, PD98059, prior to the addition of Lipo-PGE1. Lipo-PGE1-inhibited collagen mRNA expression and total soluble collagen production were recovered by pretreatment with PD98059. Moreover, Lipo-PGE1 directly induced the phosphorylation of ERK. Furthermore, silencing of Ets-1 recovered Lipo-PGE1-inhibited collagen production and PD98059 blocked Lipo-PGE1-enhanced Ets-1 expression. The present study reveals an important role for Lipo-PGE1 as a negative regulator of collagen gene expression and production via ERK/Ets-1 signaling. These results suggest that Lipo-PGE1 could potentially be a therapeutic target in diseases with deregulated collagen turnover.
[Mh] Termos MeSH primário: Alprostadil/farmacologia
Colágeno/antagonistas & inibidores
Fármacos Dermatológicos/farmacologia
Derme/efeitos dos fármacos
Fibroblastos/efeitos dos fármacos
Sistema de Sinalização das MAP Quinases/efeitos dos fármacos
[Mh] Termos MeSH secundário: Western Blotting
Linhagem Celular
Colágeno/metabolismo
Derme/enzimologia
Fibroblastos/enzimologia
Flavonoides/farmacologia
Expressão Gênica/efeitos dos fármacos
Seres Humanos
Queloide/tratamento farmacológico
Queloide/enzimologia
Masculino
Microesferas
Substâncias Protetoras/farmacologia
Inibidores de Proteínas Quinases/farmacologia
Proteína Proto-Oncogênica c-ets-1/metabolismo
RNA Mensageiro/antagonistas & inibidores
RNA Mensageiro/metabolismo
Reação em Cadeia da Polimerase em Tempo Real
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one); 0 (Dermatologic Agents); 0 (ETS1 protein, human); 0 (Flavonoids); 0 (Protective Agents); 0 (Protein Kinase Inhibitors); 0 (Proto-Oncogene Protein c-ets-1); 0 (RNA, Messenger); 9007-34-5 (Collagen); F5TD010360 (Alprostadil)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170624
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0179614


  6 / 6761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28403095
[Au] Autor:Zhu H; Xu X; Ding Y; Zhou L; Huang J
[Ad] Endereço:aZhejiang Chinese Medical University bHnagzhou First People's Hospital, Nanjing Medical University, Hangzhou, Zhejiang, China.
[Ti] Título:Effects of prostaglandin E1 on reperfusion injury patients: A meta-analysis of randomized controlled trials.
[So] Source:Medicine (Baltimore);96(15):e6591, 2017 Apr.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Prostaglandin E1 (PGE1) is widely used as a pretreatment for myocardial reperfusion injury in animal experiments. However, the cardioprotective effects of PGE1 in patients have not been established. We performed a meta-analysis to investigate whether PGE1 is cardioprotective, based on the reduction of correlative reperfusion injury events (CRIE), major adverse cardiac events (MACE), and biomarker release in patients with ischemia reperfusion injury. METHODS: The Medline, EMBASE, and Cochrane databases were searched for randomized clinical trials confirming the effects of PGE1. Two investigators independently selected suitable trials, assessed trial quality, and extracted data. RESULTS: Six studies in patients undergoing percutaneous coronary intervention (4 studies) and cardiac surgery (2 studies), comprising a total of 445 patients, were included in this review. The results showed that PGE1 reduced the incidence of CRIE (relative ratio 0.4 [95% confidence interval 0.43, 0.95]), the incidence of MACE (0.35 [0.17, 0.70]), and the level of troponin T (standardized mean difference 20.28 [20.47, 20.09]), creatine kinase-MB (-1.74 [-3.21, - 0.27]), interleukin-6 (-1.37 [-2.69, - 0.04]), and interleukin-8 (-2.05 [-2.75, - 1.34]). CONCLUSION: PGE1 may have beneficial effects on myocardial reperfusion injury in the clinic.
[Mh] Termos MeSH primário: Alprostadil/administração & dosagem
Procedimentos Cirúrgicos Cardíacos/efeitos adversos
Cardiotônicos/administração & dosagem
Traumatismo por Reperfusão Miocárdica/prevenção & controle
Intervenção Coronária Percutânea/efeitos adversos
[Mh] Termos MeSH secundário: Idoso
Biomarcadores/sangue
Procedimentos Cirúrgicos Cardíacos/métodos
Creatina Quinase Forma MB/sangue
Feminino
Seres Humanos
Incidência
Interleucina-6/sangue
Interleucina-8/sangue
Masculino
Meia-Idade
Traumatismo por Reperfusão Miocárdica/epidemiologia
Traumatismo por Reperfusão Miocárdica/etiologia
Intervenção Coronária Percutânea/métodos
Período Pós-Operatório
Ensaios Clínicos Controlados Aleatórios como Assunto
Troponina T/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS
[Nm] Nome de substância:
0 (Biomarkers); 0 (Cardiotonic Agents); 0 (IL6 protein, human); 0 (IL8 protein, human); 0 (Interleukin-6); 0 (Interleukin-8); 0 (Troponin T); EC 2.7.3.2 (Creatine Kinase, MB Form); F5TD010360 (Alprostadil)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170430
[Lr] Data última revisão:
170430
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170414
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000006591


  7 / 6761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28346210
[Au] Autor:McCluskey SV; Kirkham K; Munson JM
[Ad] Endereço:Mayo Clinic Rochester, Rochester, Minnesota. mccluskey.susan@mayo.edu.
[Ti] Título:Stability of Alprostadil in 0.9% Sodium Chloride Stored in Polyvinyl Chloride Containers.
[So] Source:Int J Pharm Compd;21(2):150-153, 2017 Mar-Apr.
[Is] ISSN:1092-4221
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The stability of alprostadil diluted in 0.9% sodium chloride stored in polyvinyl chloride (VIAFLEX) containers at refrigerated temperature, protected from light, is reported. Five solutions of alprostadil 11 mcg/mL were prepared in 250 mL 0.9% sodium chloride polyvinyl chloride (PL146) containers. The final concentration of alcohol was 2%. Samples were stored under refrigeration (2°C to 8°C) with protection from light. Two containers were submitted for potency testing and analyzed in duplicate with the stability-indicating high-performance liquid chromatography assay at specific time points over 14 days. Three containers were submitted for pH and visual testing at specific time points over 14 days. Stability was defined as retention of 90% to 110% of initial alprostadil concentration, with maintenance of the original clear, colorless, and visually particulate-free solution. Study results reported retention of 90% to 110% initial alprostadil concentration at all time points through day 10. One sample exceeded 110% potency at day 14. pH values did not change appreciably over the 14 days. There were no color changes or particle formation detected in the solutions over the study period. This study concluded that during refrigerated, light-protected storage in polyvinyl chloride (VIAFLEX) containers, a commercial alcohol-containing alprostadil formulation diluted to 11 mcg/mL with 0.9% sodium chloride 250 mL was stable for 10 days.
[Mh] Termos MeSH primário: Alprostadil/química
Embalagem de Medicamentos
Excipientes/química
Inibidores da Agregação de Plaquetas/química
Cloreto de Polivinila/química
Cloreto de Sódio/química
Vasodilatadores/química
[Mh] Termos MeSH secundário: Alprostadil/farmacologia
Alprostadil/efeitos da radiação
Cromatografia Líquida de Alta Pressão
Temperatura Baixa
Composição de Medicamentos
Estabilidade de Medicamentos
Armazenamento de Medicamentos
Concentração de Íons de Hidrogênio
Soluções Isotônicas
Luz
Inibidores da Agregação de Plaquetas/farmacologia
Inibidores da Agregação de Plaquetas/efeitos da radiação
Cloreto de Sódio/efeitos da radiação
Fatores de Tempo
Vasodilatadores/farmacologia
Vasodilatadores/efeitos da radiação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Excipients); 0 (Isotonic Solutions); 0 (Platelet Aggregation Inhibitors); 0 (Vasodilator Agents); 451W47IQ8X (Sodium Chloride); 9002-86-2 (Polyvinyl Chloride); F5TD010360 (Alprostadil)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170619
[Lr] Data última revisão:
170619
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170328
[St] Status:MEDLINE


  8 / 6761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28280146
[Au] Autor:Andersson DP; Trolle Lagerros Y; Grotta A; Bellocco R; Lehtihet M; Holzmann MJ
[Ad] Endereço:Department of Medicine, Karolinska Institutet, Unit of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden.
[Ti] Título:Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction.
[So] Source:Heart;103(16):1264-1270, 2017 Aug.
[Is] ISSN:1468-201X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Erectile dysfunction (ED) is associated with an increased risk of cardiovascular disease in healthy men. However, the association between treatment for ED and death or cardiovascular outcomes after a first myocardial infarction (MI) is unknown. METHODS: In a Swedish nationwide cohort study all men <80 years of age without prior MI, or cardiac revascularisation, hospitalised for MI during 2007-2013 were included. Treatment for ED, defined as dispensed phosphodiesterase-5 inhibitors or alprostadil, was related to risk of death, MI, cardiac revascularisation or heart failure. RESULTS: Forty-three thousand one hundred and forty-five men with mean age 64 (±10) years were included, of whom 7.1% had ED medication dispensed during a mean 3.3 years (141 739 person-years) of follow--up. Men with, compared with those without treatment for ED, had a 33% lower mortality (adjusted HR 0.67 (95%CI 0.55 to -0.81)), and 40% lower risk of hospitalisation for heart failure (HR 0.60 (95% CI 0.44 to 0.82)). There was no association between treatment with alprostadil and mortality. The adjusted risk of death in men with 1, 2-5 and >5 dispensed prescriptions of phosphodiesterase-5 inhibitors was reduced by 34% (HR 0.66 (95% CI 0.38 to 1.15), 53% (HR 0.47 (95% CI 0.26 to 0.87) and 81% (HR 0.19 (95% CI 0.08 to 0.45), respectively, when compared with alprostadil treatment. CONCLUSIONS: Treatment for ED after a first MI was associated with a reduced mortality and heart failure hospitalisation. Only men treated with phosphodiesterase-5 inhibitors had a reduced risk, which appeared to be dose-dependent.
[Mh] Termos MeSH primário: Alprostadil/uso terapêutico
Disfunção Erétil/tratamento farmacológico
Infarto do Miocárdio/epidemiologia
Inibidores da Fosfodiesterase 5/uso terapêutico
Medição de Risco
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Causas de Morte/tendências
Relação Dose-Resposta a Droga
Disfunção Erétil/complicações
Seguimentos
Seres Humanos
Masculino
Meia-Idade
Infarto do Miocárdio/etiologia
Prognóstico
Estudos Retrospectivos
Fatores de Risco
Taxa de Sobrevida/tendências
Suécia/epidemiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Phosphodiesterase 5 Inhibitors); F5TD010360 (Alprostadil)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171008
[Lr] Data última revisão:
171008
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170311
[St] Status:MEDLINE
[do] DOI:10.1136/heartjnl-2016-310746


  9 / 6761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28259984
[Au] Autor:Kuroyanagi G; Tokuda H; Yamamoto N; Kainuma S; Fujita K; Ohguchi R; Matsushima-Nishiwaki R; Kozawa O; Otsuka T
[Ad] Endereço:Department of Orthopedic Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi 467­8601, Japan.
[Ti] Título:Attenuation of prostaglandin E1­induced osteoprotegerin synthesis in osteoblasts by normoxic HIF inducers.
[So] Source:Mol Med Rep;15(4):1847-1852, 2017 Apr.
[Is] ISSN:1791-3004
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:Mimosine, which is a natural plant amino acid present in the Leucaena genus, is able to induce hypoxia­inducible factors (HIFs). Previous evidence has indicated that HIF regulates angiogenesis­osteogenesis coupling in bone metabolism, and it has previously been reported that mimosine inhibits prostaglandin (PG)F2α­induced osteoprotegerin (OPG) synthesis without affecting interleukin­6 (IL­6) production in osteoblast­like MC3T3­E1 cells. In addition, PGE1 has been demonstrated to induce OPG synthesis via activation of p38 mitogen­activated protein (MAP) kinase and stress­activated protein kinase/c­Jun N­terminal kinase (SAPK/JNK) in these cells, and PGE1 stimulates IL­6 production via the activation of protein kinase A. In the present study, the effects of mimosine on the PGE1­stimulated synthesis of OPG and IL­6 were investigated in osteoblast­like MC3T3­E1 cells. The concentrations of OPG and IL­6 were measured using relevant ELISA kits. OPG mRNA was measured by semi­quantitative reverse transcription polymerase chain reaction. The phosphorylation of p38 MAP kinase and SAPK/JNK was analyzed by western blotting. Mimosine significantly reduced PGE1­induced release of OPG and OPG mRNA expression levels without affecting the release of IL­6. In addition, deferoxamine, which is also a normoxic HIF inducer, significantly inhibited PGE1­induced OPG release and OPG mRNA expression levels; however, it had little effect on IL­6 release. Furthermore, mimosine and deferoxamine failed to affect PGE1­stimulated phosphorylation of p38 MAP kinase or SAPK/JNK. These results strongly suggest that normoxic HIF inducers attenuate PGE1­stimulated OPG synthesis without affecting IL­6 production in osteoblasts.
[Mh] Termos MeSH primário: Alprostadil/metabolismo
Desferroxamina/farmacologia
Fator 1 Induzível por Hipóxia/agonistas
Mimosina/farmacologia
Osteoblastos/efeitos dos fármacos
Osteoprotegerina/metabolismo
[Mh] Termos MeSH secundário: Animais
Linhagem Celular
Fabaceae/química
Fator 1 Induzível por Hipóxia/metabolismo
Interleucina-6/metabolismo
MAP Quinase Quinase 4/metabolismo
Camundongos
Mimosina/química
Osteoblastos/citologia
Osteoblastos/metabolismo
Osteoprotegerina/genética
Fosforilação/efeitos dos fármacos
Biossíntese de Proteínas
RNA Mensageiro/genética
Proteínas Quinases p38 Ativadas por Mitógeno/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hypoxia-Inducible Factor 1); 0 (Interleukin-6); 0 (Osteoprotegerin); 0 (RNA, Messenger); 500-44-7 (Mimosine); EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases); EC 2.7.12.2 (MAP Kinase Kinase 4); F5TD010360 (Alprostadil); J06Y7MXW4D (Deferoxamine)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170512
[Lr] Data última revisão:
170512
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170306
[St] Status:MEDLINE
[do] DOI:10.3892/mmr.2017.6177


  10 / 6761 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:28255370
[Au] Autor:Bratu O; Oprea I; Marcu D; Spinu D; Niculae A; Geavlete B; Mischianu D
[Ad] Endereço:Department of Urology, "Dr. Carol Davila" Central Military Universitary Emergency Hospital, Bucharest, Romania ; Clinical Department No. 3, "Carol Davila" University of Medicine and Pharmacy Bucharest, Romania.
[Ti] Título:Erectile dysfunction post-radical prostatectomy - a challenge for both patient and physician.
[So] Source:J Med Life;10(1):13-18, 2017 Jan-Mar.
[Is] ISSN:1844-3117
[Cp] País de publicação:Romania
[La] Idioma:eng
[Ab] Resumo:Post-radical prostatectomy erectile dysfunction (post RP ED) is a major postoperative complication with a great impact on the quality of life of the patients. Until present, no proper algorithm or guideline based on the clinical trials has been established for the management of post RP ED. According to literature, it is better to initiate a penile rehabilitation program as soon as possible after surgery than doing nothing, in order to prevent and limit the postoperative local hypoxygenation and fibrosis. The results of numerous clinical trials regarding the effectiveness of the phosphodiesterase 5 inhibitors therapy on post RP ED have made them the gold standard treatment. Encouraging results have been achieved in studies with vacuum erectile devices, intraurethral suppositories with alprostadil and intracavernosal injections, but due to their side effects, especially in the cases of intracavernosal injections and intraurethral suppositories, their clinical use was limited therefore making them a second line option for the post RP ED treatment. What should not be forgotten is that penile implant prosthesis has proven very effective, numerous studies confirming high rates of satisfaction for both patients and partners.
[Mh] Termos MeSH primário: Disfunção Erétil/etiologia
Médicos
Prostatectomia/efeitos adversos
[Mh] Termos MeSH secundário: Alprostadil/uso terapêutico
Disfunção Erétil/tratamento farmacológico
Seres Humanos
Masculino
Prótese de Pênis
Inibidores da Fosfodiesterase 5/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Phosphodiesterase 5 Inhibitors); F5TD010360 (Alprostadil)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170501
[Lr] Data última revisão:
170501
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170304
[St] Status:MEDLINE



página 1 de 677 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde